Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).

摘要: Objective. To report a case of who patient developed clinical and radiographical evidence interstitial lung disease (ILD) on erlotinib after having tolerated gefitinib therapy.Case Summary. A 58-year-old man with stage IV non-small-cell cancer (NSCLC) failed first second line chemotherapy. He then received gefitinib, small molecule epidermal growth factor receptor (EGFR) inhibitor, therapy which was well tolerated, but did cause grade 1 rash. On the patient’s remained stable for seven months. Subsequent progression treated newer EGFR erlotinib. After 5 days therapy, presented sore throat dyspnea, followed by 2 rash significant hemoptysis. Erlotinib discontinued three days, during time his symptoms abated. restarted again throat, dyspnea severe hemotpysis, to 3. discontin...